Background: The optimal antithrombotic therapies for transcatheter aortic valve implantation (TAVI) and MitraClip implantation have not been well established. We conducted a narrative review from currently available studies between January 2002 and May 2016 to highlight the advantages and disadvantages of antithrombotic therapy use in cardiac catheter-based therapeutic techniques. Recently, these techniques have dramatically altered the approach towards valvular heart diseases management. The introduction into clinical practice, of TAVI for severe aortic stenosis and MitraClip for mitral regurgitation, has revolutionized interventional cardiology. However, TAVI is associated with a risk of cerebral embolization and ischaemic vascular events leading to neurological impairment and even death. These ischaemic complications might occur perioperatively or much later, although the estimated rate of occurrence is variable.
Conclusion: We will discuss prior experience with MitraClip for antithrombotic use. It is imperative for patients undergoing transcatheter valvular interventions to have optimal antithrombotic therapy that balances between ischaemic and haemorrhagic complications. The appropriate timing, combination, and duration of antithrombotic medications need consensus to weigh between the efficacy, efficiency and adverse effects in patients with transcatheter valvular interventions.
Keywords: TAVI, MitraClip, aortic stenosis, SAVR, antiplatelet, antithrombotic.
Current Concepts and Perspectives on Connexin43: A Mini Review
Current Protein & Peptide Science Editorial (Thematic Issue: Calcium in Heart Disease: The Ubiquitous Ion)
Medicinal Chemistry Simultaneous Determination of Six Components in Jingzhiguanxin Tablet by High-Performance Liquid Chromatography
Current Pharmaceutical Analysis Tissue Doppler Imaging in Coronary Heart Diseases and Heart Failure: An Up to Date
Recent Patents on Medical Imaging (Discontinued) Treatment of Experimental Myocarditis via Modulation of the Renin-Angiotensin System
Current Pharmaceutical Design Mediterranean Diet and the Metabolic Syndrome: The Role of Protein
Current Nutrition & Food Science Cardiac Metabolism in Myocardial Ischemia
Current Pharmaceutical Design Vascular C-Reactive Protein in the Pathogenesis of Coronary Artery Disease:Role of Vascular Inflammation and Oxidative Stress
Cardiovascular & Hematological Disorders-Drug Targets The Developing Role of Neuregulin1 In Cardiac Regenerative Stem Cell Therapy
Current Pharmaceutical Design The Role of Myocardial Collagen Network in Hypertensive Heart Disease
Current Hypertension Reviews The Potential Role of Antioxidants in Metabolic Syndrome
Current Pharmaceutical Design Recent Advances in the Discovery and Development of Direct Coagulation Factor Xa Inhibitors
Current Pharmaceutical Design Cytoprotective and Antiproliferative Effects of HMG-CoA Reductase Inhibitors
Current Enzyme Inhibition Estrogen Receptors: Molecular Interactions, Virtual Screening and Future Prospects
Current Topics in Medicinal Chemistry Cytokine Gene Variants as Predictors of Type 2 Diabetes Mellitus
Current Diabetes Reviews From Mars to Venus: Gender Differences in the Management and Outcomes of Acute Coronary Syndromes
Current Pharmaceutical Design Does HbA1cc Play a Role in the Development of Cardiovascular Diseases?
Current Pharmaceutical Design Cardiac Stem Cell Characteristics in Physiological and Pathological Conditions
Current Pharmaceutical Design Lipoprotein Lipase and Atherosclerosis
Current Vascular Pharmacology The Mechanisms Behind the Biological Activity of Flavonoids
Current Medicinal Chemistry